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ABSTRACT 
In this paper we present an extension of an automata approach proposed by S. Blower (1998) to describe the 
tuberculosis progression in a bi-dimensional space. In our extended model, the vaccination was included as an 
inhibitory variable in order to study its influence on the behavior of the tuberculosis spread. Our simulations 
showed  that  the  earlier  the  vaccine  is  administered  in  the  population,  the  lower  the  number  of  infected 
individuals, as expected for an in vivo system. However, our results also indicated that although the usual 
vaccination processes help reducing the strength of infection, the disease is not extinct, remaining the endemic 
state at low levels. These results strongly suggest that further actions are needed to increase the effectiveness of 
immunizations. 
Keyword: Simulation, epidemic, tuberculosis, cellularautomata. 
 
I.  INTRODUCTION 
Tuberculosis  (TB)  is  an  important  health  issue 
for  Brasil  and  many  others  around  the  world.  It  is 
estimated that about one third of the world population 
is already infected with tuberculosis (Mtb). Each year 
8.8  million  new  cases  are  reported  [18].  TB  is  a 
disease that over the years has been concerning the 
world  society,  it  has  high  risk  of  infection  and 
contagion. A person infected is able to infect around 
10 to 15 people over a period of one year [2]. The 
Mtb  infection  can  be  transmitted  by  coughing, 
sneezing,  singing,  speech,  breathing,  and  even  by 
tracheotomy  individuals.  This  is  a  slow-developing 
disease, which in most cases occurs after two years 
after initial infection. The advent of vaccination with 
BCG and with increasing effectiveness of treatment 
reduced the chronic disease  and its transmission in 
this community.  
The treatments are in permanently evolution in 
past 50 years they were able to change the face of the 
disease  appearance,  move  to  the  third  age.  The 
immunity occurs with the primary contact with the 
bacteria  and  vaccination,  reduces  susceptibility  to 
infection, making the state of the population switch to 
the  recover  state,  during  until  the  immunity  falls. 
Previous  studies  show  that  the  immune  response 
given by the vaccine in people already sensibilized 
by the Mtb from a primary infection does not bring 
an  improvement  in  protection  [19].  Some  authors 
state that the main effect of BCG is to reduce disease 
progression  more  than  the  actual  risk  of  infection 
(Smith et al. 2000). In order to help health services, 
indicating the crow of the disease, the advance in  
 
some neighborhood and indicate the epidemiological 
emergence,  showing  where  it  emerges,  helping  the 
decision making to becoming more dynamic to solve 
the  potential  problem.  With  this  purpose  was 
developed interdisciplinary urgent action, which has 
a bio-mathematical models and computer simulation 
dynamics.  The  idea  of  a  dynamic  model  that  is 
formed  based  on  discrete  time  and  consists  of  a 
spatial grid of cells filled in time and space [16]. In 
most  cases,  the  classical  models  (SIS,  SIRS  or 
SEIRS)  with  transmission  rate  and  population 
constant, present a unique endemic equilibrium. This 
paper shows the effectiveness of BCG vaccination in 
individuals  of  different  age  groups,  studying  the 
dynamics of tuberculosis in these people. 
 
II.  METODOLOGY. 
In orderto developaprobabilisticcellular automata 
model, represented inacomputational grid where each 
cell  representsanindividualandits  location.  This 
personisendowed  withastatusthatgives  itsplacein  the 
dynamics.  The  epidemicdissemination  can 
beconsideredas  aset  ofstatesdescribedas 
follows:Susceptible(hoping  toget  infected), 
latent(infected  butwith  the  bacteriaunder  control), 
Infected(bacteria  activelytransmitsthedisease) 
Recovered(immune  to  disease) 
andifimmunityislowyou  cango  backto 
thestateSusceptible(when 
passinghasimmunityinsomecases)  (SEIRS)  [5]. 
Thediagramoftransition  between  statesis 
representedinFigure 1 
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Figure 1: SEIR state model with vaccine, where  is 
the Power of infection,  is the recovery rate,  is the 
rate  of  infection  and   is  the  mortality  rate,  is  an 
adaptation of  BLOWER, SM, 1998 model. 
Source: BLOWER, SM, et all, 1998. 
The main feature of the used model is the ability 
to  develop  locally.  Since  the  tuberculosis  bacillus 
needs necessarily of an direct and prolonged contact, 
since the disease develop slowly a concern should be 
taken in the model. The first infection may manifest 
in months or years. The global transmission exists, 
but  is  uncommon.  For  people  from  the  same 
population,  has  the  capacity  of  global  transition  is 
given by the total number of infected individuals in 
the  network,  due  to  their  ability  to  walk  (pG),  is 
described by the equation: 
ProbGlobal  =  *(TS_Total  +  TR_Total)/N; 
where  0≤  ρ≤1    (1),  where  TS  are  the  susceptible 
infected people, the TR are the resistant infected, the 
N is the total number of individuals in the grid and 
and  are  parameters  used  for  small  (forming 
clusters) and long distance (mean field) [9], knowing 
that pL>>pG. 
To influence the population who lives around of 
a  infected  individual,  local  spread  (pL),  being  its 
ability  of  infect  given  by  the  equation  2,  where 
ProbTypeS is the probability to susceptible infected 
pass the illness: 
  pL  =  1.0  -  (ProbTypeS  +  ProbTypeR  - 
ProbTypeS*ProbTypeR). Where:  
  ProbTypeS = 1.0 - pow(1.0 - lS, CountTS);   
  ProbTypeR = 1.0 – pow (1.0 - LambdaR, 
(double)CountTR). 
Wasusedto  describe  theindividualbehavior  with 
his  neighborhood  theMooremodel,  whereaperson  is 
abletogetin  contactwitheveryone  around,  the 
probalility  ofinfection  isgiven  byequation2. 
Thedynamicsis  givenas  follows,  the 
infectedindividualaccount  the  number  of  infected 
neighborsand  look  for  the  susceptible.  From 
therewithacertain  probabilitypL=1-(1-λ)
n, 
wherenisthenumber  ofinfected  individuals,passes 
intoa  latent 
state.Withaprobabilityv,whichrepresentstime, 
socioeconomic,environmental  and  stateof 
immunity,the susceptible individualbecomesinfected, 
infectedaftertreatmentwelldone  become 
recoveredclosingthechain. 
 
III.  RESULTS. 
The  simulations  represented  in  this  article 
demonstrate  the  TB  behavior  when  submitted  to 
interventions.  The  control  parameters  of  bacilli 
spread were studied and taken from an mean of the 
Brasilian govern database and from others articles so 
the amounts should be approximate real life. The data 
simulated  wore  compared  with  the  literature 
verifying the model efficacy.  
In the figure 2 show that inspire of the vaccine 
has  a  significant  importance  for  the  primary 
tuberculosis  prevention  and  some  importance  for 
pulmonary TB, the BCG is not able to put away the 
danger, letting the disease always at endemic state, 
only  ranging  the  number  of  infected  people.  Was 
studied  the  vaccine  in  different  levels  of  efficacy, 
35%,  65%  and  85%.When  the  efficacy  of  vaccine 
was putted at 90% of efficacy, but now was changed 
the time of shooting to: 1st, 10, 40, 80 years of the 
simulation,  with  or  without  the  treatment  or 
chemoprophylaxis.  The  results  show  that  by 
increasing and decrease the efficiency, changing the 
date of the shooting not only decreases the level of 
infection, but also alter the life of the vaccine, how 
long protection lasts increases. Can be seen that the 
greater efficacy in vaccine and lower the age at which 
it  applies  the  vaccine  has  a  less  variation  between 
peaks and valleys, thus reducing the likelihood of an 
outbreak due to another event, such as opportunistic 
infections. 
Once  the  vaccine  is  not  only  able  to  end  the 
pathogen,  the  only  way  to  eradicate  the  disease  is 
thought the treatment, the treatment was used at a phi 
of 0.1 and 0.5 sigma, which are respectively the per 
capita  rate  of  treatment  and  the  rate  per  capita  of 
chemoprophylaxis, used for third world countries, a 
number  of  treaties  of  70%  and  50%  in 
chemoprevention,  we  studied  with  and  without 
vaccine, 90% of the population were vaccinated and 
the vaccine efficiency was 85% and still dividing at 
ages of vaccination, 5 , 10, 20 and 50 it can be shown 
at the figure 1b. 
The figure 3 show a treatment applied in some 
time after or before the year 5, 10, 20 and 50. This 
particular  study  shows  that  the  disease  is  not 
completely,  the  epidemic  wave  drops,  but  the 
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way  in  low  level.  If  vaccine  is  used  perceives 
that the number of infected people levels drops even 
more but only when the shots are made between 0 
and  5  years  that  the  TB  tends  to  disappear,  but  it 
doesn’t.  The figure shows too that if the vaccine is 
applied exactly at the first years, 0,1, 2, 3, 4 and 5 
percent ofvaccinated people are greater than 85% and 
counting  with  a  good  treatment  that’s    possible  to 
exterminated the tuberculosis in the finite population. 
Figure 2 – Tuberculosis time evolution, (a) Vaccine 
with 35% of efficacy, administrated in the 1
oano, 
10
oano, 40
oano e 80
oano. (b) Vaccine with 65% of 
efficacy, administrated in the 1
oano, 10
oano, 40
oano e 
80
oano. (c) Vaccine with 85% efficacy, administrated 
in the 1
oano, 10
oano, 40
oano e 80
oano. (d) Show the 
contrast between the tree efficacy’s at the first year. 
Figura 3 - Time evolution of tuberculosis, with a 
90% percentage of vaccinated and 85% of vaccine 
efficacy. (a) Treatment in the 5th, the first 5 years 
and after 5 years, with or without vaccine. (b) C Frederico Fronza et al Int. Journal of Engineering Research and Applications          www.ijera.com 
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treatment in the 10th, the first 10 years and after 10 
years, with or without vaccine. (c) Treatment at the 
20th, the first 20 years and after 20 years, with or 
without vaccine. (d) Treatment at the 50th, the first 
50 years and after 50 years, with or without vaccine. 
 
IV.  DISCUSSION 
In  the  tuberculosis  time  behavior  study,  taking 
into  account  the  age,  gender  and  socioeconomic 
customs, this study aimed to verify the effectiveness 
of  BCG  as  a  prophylactic  measure.  By  successive 
simulations  using  different  vaccine  efficacy, 
vaccinating  at  different  ages  and  finally  using  the 
treatment. It can be seen that although the efficacy 
has  a  little  influence  on  the  performance  of  the 
disease, is able to reduce the force of infection, due 
to,  once  vaccinated  the  chances  of  getting  infected 
diminishes. 
Figure 1 focuses on the different rates of vaccine 
efficacy, 35%, 65% and 85%, with age vaccination, 
1, 10, 40 and 80. The results shows that in the first 
year  is  was  found  the  best  immune  response  to 
vaccine.  According  to  the  Andersen  study, 
vaccination  of  the  newborn,  which  in  our  system 
represents the first year, is where the greatest relation 
age and vaccine efficacy (Andersen, 2007). So it was 
simulated for different efficiencies and different ages 
and  finally  settled  the  prime  age,  ranging  only  the 
vaccine's effectiveness. Thus it was realized that only 
with the variation in vaccine efficacy is not enough to 
achieved a significant improvement, the treatment is 
necessary to break down the disease cycle. 
The finding is in agreement with the Andersen 
(2005), which questions the real effectiveness of the 
vaccine, showing that the protective performance of 
BCG decays with the coming years to maximum 10 
to 20 years of protection. When dealing with efficacy 
of the vaccine in graph 2, it was explored between 35 
and 85%, since there are reports suggest an efficacy 
of  BCG  for  0  to  80%  (Pereira  et  al.,  2007). 
BARRETO, (2006), reports that the power of BCG 
action varies from 0 to 86%, this variation may be 
caused  due  to  the  characteristics  of  the  individual, 
their habitat, the strain of the bacillus among others. 
The  finding  that  underscores  the  controversy  about 
the  efficacy  of  BCG,  since  there  was  no  great 
difference  in  different  efficacies  after  85% 
(SUGAWARA et al, 2009). 
Regarding vaccination coverage in this paper we 
used a coverage of 90% of individuals are vaccinated, 
this number varies with the environment, town and 
over the years in a given population. MIRANDA et al 
(1995)  suggested  that  BCG  vaccination  coverage 
varies  from  79  to  85%.  MORAES  et  al  (2003), 
reports that the coverage of BCG in the metropolitan 
region of Sao Paulo reaches 97.8%. 
YOUNG, et al (2008) talks about the association 
between the BCG efficacy and the body's own ability 
to reject the disease without any intervention, since 
only 10% of the diseases manifests in its active form. 
In the same study was called into question the real 
effectiveness  of  the  vaccine  against  pulmonary 
tuberculosis. 
BIERRENBACH,  et  al.  (2007)  study  is  in 
agreement  with  the  work  proposed  here,  once  the 
vaccine  is  applied  the  frequency  of  new  cases  of 
tuberculosis decrease mainly in the in the simulation 
first  years,  after  some  time  the  new  cases  of  the 
disease start to grow back and If that is not properly 
treated,  the  disease  itself  stabilized  and  becomes 
endemic.  However,  with  a  high  rate  of  infected 
people  or  the  contraction  of  immune  depressor 
sickness  represents  a  major  risk  for  the  resurgence 
and possible development of an epidemic outbreak. 
RUFINO (1977) reports that with at least 55.5% 
BCG  efficacy  it  would  be  enough  to  keep  the 
relationship economy  – spending.  According to the 
study proposed the vaccine is not able to replace the 
treatment, even with a 100% efficacy vaccine. In the 
literature can be seen that the efficacy of BCG varies 
from 50% to 87% (BARRETO, et al, 2006; SHEN, et 
al,  2008),  it  shows  that  the  BCG  that  is  produced 
today is not sufficient to snuff out the bacillus.  
VASCONCELOS  et  al  (2009)  describes  the 
ineffectiveness  of  BCG  for  preventing  pulmonary 
TB,  which  is  in  agreement  with  our  findings. 
However, the author reports on his study that in the 
process  of  developing  a  new  vaccine  against 
tuberculosis,  which  will  be  effective  against 
secondary tuberculosis, would be a big step toward 
the end of tuberculosis.  
However is  possible to see in the result, in the 
first  phase  of  tuberculosis  plus  the  use  of  vaccine 
shows  a  substantial  decline,  this  drop  was  already 
observed  by  ALMEIDA  (1990)  in  his  study  that 
compared the mortality occurring in children under 1 
year, before and after vaccine, showing that there is a 
regression  from  7.9  times  after  the  vaccine.  This 
demonstrates  that  the  protection  afforded  by  the 
vaccine is in the first life age. 
FU (2002) shows a historical evidence that in a 
population where individuals go through a network, 
either a city or a country, there is a chance that an 
infection after an outbreak will become endemic. Our 
findings corroborate this claim, since the tuberculosis 
disease  always  tends  to  be  endemic  in  the  state, 
according to the proposed model. 
The figure 2 shows the endemic characteristic of 
tuberculosis, which remains throughout its existence, 
to looking at the  figure 2 it’s clear to  see that the 
natural trend of tuberculosis over time is shown in 
linear average, this means that there are a outsized 
changes  in  its  etiologic  characteristic,  unless 
something  goes  in  advent  that  will  strengthen  the 
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The  disease  manifests  as  a  tendency  in  many 
endemic  countries,  with  a  higher  incidence  in 
developing  countries,  that  is  the  case  of  Brazil, 
affecting 10% to 15% of immunocompetent patients 
and  50%  to  70%  of  individuals  with  acquired 
immunodeficiency  syndrome  (RIQUELME  ,  2006). 
By  observing  the  second  figure  it  is  clear  that 
Mycobacterium tuberculosis is no longer follow its 
natural  tendency,  stabilized,  it  can  happen  by 
feedback,  genetic  and  environmental  factors,  the 
infection requires a long time relied on the bacterium, 
fee  high  virulence,  and  hostile  conditions  of  life, 
which makes the transmission and spread, giving the 
human body able to make the first fight the disease 
(PENNA, 1988). 
Tuberculosis  is  an  injury  that  the  environment 
itself gives man a natural vaccine, characterizing the 
stability of the disease without the presence of any 
adverse condition, the HIV can change the constancy 
of the disease and enhances  the risk of developing 
active  TB  (KERR-BRIDGES,  ET  all.,  1997). 
GLYNNA (1997) and Vasconcelos (2009), talk about 
how  leprosy  and  HIV  are  considered  extremely 
dangerous  to  be  related  to  tuberculosis,  are  largely 
responsible  for  its  appearance  and  /  or  resurgence, 
and that the combination of BCG vaccine in people 
with  immunosuppression  can  be  very  dangerous. 
Confirming  the  hypothesis  of  this  study  in  which 
only the associate diseases that depress the immune 
system are able to take the trend of endemic TB. 
Figure 1 shows the trend of tuberculosis in time 
for a vaccinated population in year 1, 10, 20, 40 and 
80, with an efficiency of 35%. The choice of vaccine 
efficacy for this experiment was made because is a 
low  percentage,  and  it  is  in  agreement  with  the 
variation of effectiveness according with (PEREIRA 
et al., 2007). With an effective so low it is clear that 
the spread and stabilization, are not much different 
for all ages. In the first years of life, 0 to 5 years, can 
be  observed  the  highest  percentage  of  BCG 
effectiveness, 84%, making the choice of one year as 
the  key  year  for  the  best  use  of  the  drug.  The 
variation  in  vaccine  efficacy  also  suggests  the  age 
difference  in  a  population  where  the  highest 
efficiency  is  obtained  in  the  first  five  years  of  life 
with a protection given to 85% to 87%, however over 
the years the protective effect decreases. 
Over  the  years  as  seen  in  the  figure  2  the 
effectiveness begins to decrease,  which leads  us to 
choose the 10th year since between the ages, 1 and 15 
years  the  BCG  efficacy  drops  about  59%,  proving 
what  was  suggested  in  the  resuts  (Barreto  et  all, 
2006). In this trend the vaccine administrated in the 
years  20  and  40  shows  a  higher  degradation  in  its 
protective effect, combined with the worst habits of 
life  of  a  young  population,  cases  of  tuberculosis 
increasing  in  this  age  group.  From  the  age  of  50 
despite  the  older  population  better  watch  out,  your 
body,  the  defense  no  longer  works  as  before,  their 
effectiveness  drops  to  lowest  index  to  measure  the 
mortality rate increases, Wales (1998), discusses the 
growth of the adults deaths for young people between 
20  and  49,  representing  59.7%  of  deaths  and  the 
decline in deaths to less than 20 and greater than 50 
years. 
SHEN et al (2008) presents in his paper that not 
only  has  the  vaccine  more  effectiveness  when 
younger, but also the duration of its protective effect 
last longer, as suggested in the paper. The attenuation 
of  immunity  caused  by  BCG,  decays  with  time  as 
evidenced by this hypothesis DOHERTY (2005) that 
shows  even  with  the  continued  reduction  of  the 
protective  effect  conferred  by  BCG  vaccination 
compromises the body ability to stimulate production 
of antibodies and immune memory. 
The treatment is taken as the only way to really 
remove the bacillus of the human body system, but 
only with a treatment well done from start to finish. 
Jasmer  et  al  (2004),  describes  in  his  article  that 
treatment well made, properly led from the beginning 
to  the  end  represents  a  healing  capacity  of  over 
97.5%  of  cases  and  also  alerts  on  the  problem  of 
treatment abandonment  which gives strength to the 
mycobacterium  tuberculosis  making  it  more 
resistant and difficult to treat. VALLEJO (1994) calls 
attention  to  the  fact  that  if  the  treatment  is  done 
correctly and has sooner start it can be a cure in about 
six months, explaining the sharp drop shown in figure 
3 where the processing is done with efficiency and 
accuracy. 
The figure 2 shows the tuberculosis in time with 
and without vaccine, at the ages already mentioned in 
this discussion, but at this time was add the treatment 
as well. As seen in this work the BCG is not able to 
suppress the bacillus, so the treatment is necessary to 
cease  the  illness,  since  only  effective  treatment  is 
able  to  eliminated  it  (Andersen,  2005).  The  figure 
portrays the treatment of individuals, minor and equal 
to 5 years old, using the fifth year as reference. In this 
discussion  it  was  resolute  that  at  the  ages  0-5  is 
where  can  get  the  best  results  for  contraceptive 
measures.  Was  also  used  in  this  simulation  the 
treatment  well  done  and  ineffective  treatment,  a 
treatment  that  was  not  completed,  the  incomplete 
treatment reflects a major problem for public health, 
since the bacillus becomes resistant to drugs (LIMA 
et al, 2001). 
The  settled  treatment  on  the  year  fifth  can  be 
called an early treatment, as it is done in children has 
a  good  adhesion,  making  it  the  fastest  and  safest 
treatment (LIMA et al, 2001; Perreira et al, 2007). It 
can be seen that within an increasing age makes the 
treatment with or without vaccine, with a well done 
treatment,  ruled  at  any  age  the  real  improvement 
occurs.  The  vaccine  can  help  a  bad  treatment, C Frederico Fronza et al Int. Journal of Engineering Research and Applications          www.ijera.com 
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however it appears an increase of infected individuals 
resistant. 
In  his  study  Koriki  (2008)  reports  that  at  the 
equilibrium,  endemic,  the  tuberculosis  is  able  to 
change your state depending on external conditions, 
as  associated  diseases,  differences  in  climate, 
inhospitable  regions,  as  well  as  the  population 
socioeconomic  level.  This  information  goes  in 
agreement with was showed on the results obtained 
in this work. In its endemic form, the infection only 
can become active with a disturbance in the disease 
routine.  
 
V.  CONCLUSION. 
The proposed model was used to aid and check 
the decision making regarding to the epidemiology of 
tuberculosis. The results showed in this paper were 
satisfactory and from them we can infer that: 
  The BCG has great accuracy and effectiveness 
for populations of individuals between the ages 0 
to  5  years.  After  this  age  the  vaccine's 
effectiveness begins to wane.  
  The vaccine is not able to influence the spread of 
pulmonary tuberculosis, showing that BCG is the 
way you made today has a positive effect, ending 
only with severe forms of primary tuberculosis.  
   Since the vaccine reduces slightly the amount of 
infected individuals in the network, the treatment 
is necessary, only the treatment is done properly 
able to shoot with tuberculosis. 
  Poor  treatment  generates  dangerous 
consequences, makes the multi resistant bacillus. 
The  above  study  did  not  focus  on  MDR,  but 
future work will be given greater attention to this 
issue.  
This  study  is  very  important  to  create  a 
discussion,  since  it  will  provide  a  different 
perspective  and  depth  on  the  observed  behavior  of 
the disease in question. The results of the works show 
the reality of tuberculosis in Brazil as well as their 
way of life, this indicates that the model can be used 
to  simulate  the  behavior  of  many  tuberculosis 
situation satisfactorily. This way you can monitor and 
study the TB from the proposed system.  
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